Delving into the Latest Updates on Pneumococcal vaccine recombinant(GlaxoSmithKline Plc) with Synapse

Overview

Basic Info

Drug Type

Prophylactic vaccine

Synonyms

Pneumococcal vaccine recombinant, S. pneumoniae adult vaccine

+ [3]

Target-

Action

stimulants

Mechanism

Immunostimulants

Therapeutic Areas

Infectious DiseasesOtorhinolaryngologic Diseases

Active Indication-

Inactive Indication

Infection of earOtitis MediaStreptococcal Infections

Originator Organization

GSK Plc

Active Organization-

Inactive Organization

GSK Plc

Drug Highest PhasePendingPhase 2

First Approval Date-

Regulation-

Login to view timeline

The purpose of this study is to 1) demonstrate the protective efficacy against acute otitis media (AOM), 2) assess safety of the GlaxoSmithKline (GSK) Biologicals' pneumococcal vaccine GSK2189242A in Native American infants aged less than 24 months, living in the southwestern US, in and around the Navajo and White Mountain Apache reservations, and 3) evaluate the impact on acute lower respiratory tract infections (ALRI) up to the second year of life.

Start Date21 May 2012

Sponsor / Collaborator

GSK Plc

NCT01262872

/ CompletedPhase 2

Impact of GSK Biologicals' 2189242A Vaccine on Nasopharyngeal Carriage, Safety and Immunogenicity When Co-administered With Routine EPI Vaccines in Infants Following Safety Assessment in Children Aged 2-4 Years in The Gambia

This study will assess the impact on nasopharyngeal carriage, safety and immunogenicity of GSK Biologicals' pneumococcal vaccine 2189242A given as a 3-dose vaccination course and co-administered with other routine paediatric vaccines in infants in The Gambia. Two formulations containing different doses of pneumococcal antigen and two different schedules will be tested in infants.

Start Date09 Feb 2011

Sponsor / Collaborator

GSK Plc

[+3]

NCT01204658

/ CompletedPhase 2

Safety, Reactogenicity & Immunogenicity of GSK Biologicals' Pneumococcal Vaccine 2189242A When Co-administered With DTPa-HBV-IPV/Hib Vaccine in Healthy Infants

This study will assess the safety, reactogenicity and immunogenicity of two formulations of GSK Biologicals' pneumococcal vaccine 2189242A given as a 3-dose primary vaccination course during the first 6 months of life followed by a booster dose at 12-15 months of age and co-administered with DTPa-HBV-IPV/Hib vaccine.

Start Date27 Sep 2010

Sponsor / Collaborator

GSK Plc

100 Clinical Results associated with Pneumococcal vaccine recombinant(GlaxoSmithKline Plc)

Login to view more data

100 Translational Medicine associated with Pneumococcal vaccine recombinant(GlaxoSmithKline Plc)

Login to view more data

100 Patents (Medical) associated with Pneumococcal vaccine recombinant(GlaxoSmithKline Plc)

Login to view more data

21

Literatures (Medical) associated with Pneumococcal vaccine recombinant(GlaxoSmithKline Plc)

01 Sep 2023·Molecular Immunology

ΔA146Ply-HA stem protein immunization protects mice against influenza A virus infection and co-infection with Streptococcus pneumoniae

Article

Author: Wang, Hanyi ; Xu, Wenlong ; Li, Lian ; Yang, Rui ; Zhang, Xuemei ; Yuan, Yuan ; Yin, Yibing ; Xiao, Jiangming ; Guo, Ting

Influenza virus (IV) is a common pathogen affecting the upper respiratory tract, that causes various diseases. Secondary bacterial pneumonia is a common complication and a major cause of death in influenza patients. Streptococcus pneumoniae (S. pneumoniae) is the predominant co-infected bacteria in the pandemic, which colonizes healthy people but can cause diseases in immunocompromised individuals. Vaccination is a crucial strategy for avoiding infection, however, no universal influenza vaccine (UIV) that is resistant to multiple influenza viruses is available. Despite its limited immunogenicity, the hemagglutinin (HA) stem is a candidate peptide for UIV. ΔA146Ply (pneumolysin with a single deletion of A146) not only retains the Toll-like receptor 4 agonist effect but also is a potential vaccine adjuvant and a candidate protein for the S. pneumoniae vaccine. We constructed the fusion protein ΔA146Ply-HA stem and studied its immunoprotective effect in mice infection models. The results showed that intramuscular immunization of ΔA146Ply-HA stem without adjuvant could induce specific antibodies against HA stem and specific CD4⁺ T and CD8⁺ T cellular immunity in BALB/c and C57BL/6 mice, which could improve the survival rate of mice infected with IAV and co-infected with S. pneumoniae, but the protective effect on BALB/c mice was better than that on C57BL/6 mice. ΔA146Ply-HA stem serum antibody could protect BALB/c and C57BL/6 mice from IAV, and recognized HA polypeptides of H3N2, H5N1, H7N9, and H9N2 viruses. Moreover, ΔA146Ply-HA stem intramuscular immunization had a high safety profile with no obvious toxic side effects. The results indicated that coupling ΔA146Ply with influenza protein as a vaccine was a safe and effective strategy against the IV and secondary S. pneumoniae infection.

01 Jan 2023·Frontiers in molecular biosciences

Integrated immunoinformatics and subtractive proteomics approach for multi-epitope vaccine designing to combat S. pneumoniae TIGR4.

Article

Author: Bantun, Farkad ; Jalal, Naif A ; Qusty, Naeem F ; Ashgar, Sami S ; Darwish, Abdulla ; Janahi, Essam M ; Haque, Shafiul ; Faidah, Hani

Streptococcus pneumoniae is one of the major precarious pathogens accountable for over 1.2 million fatalities annually. The key drivers for pneumococcal vaccine development involve high morbidity and mortality in over one million cases, especially in very young children and the elderly. In this study, immunoinformatics was integrated with subtractive proteomics to find antigenic proteins for designing a multi-epitope vaccine against S. pneumoniae. As prospective vaccine targets, the developed pipeline identified two antigenic proteins, i.e., penicillin-binding protein and ATP synthase subunit. Several immunoinformatics and bioinformatics resources were used to forecast T- and B-cell epitopes from specific proteins. By employing a mixture of five cytotoxic T-cell lymphocytes, six helper T-cell lymphocytes, and seven linear B-cell lymphocyte epitopes, a 392 amino acid-long vaccine was designed. To enhance immune responses, the designed vaccine was coupled with a cholera enterotoxin subunit B adjuvant. The designed vaccine was highly antigenic, non-allergenic, and stable for human usage. The stability of the vaccine with toll-like receptor-4 was evaluated by molecular docking and molecular dynamic simulation. In addition, immunological simulation was performed to test its real-world potency. The vaccine codon was then cloned in silico. Overall, this study paves the way for the development of a multi-epitope S. pneumoniae vaccine under laboratory conditions. Furthermore, the current findings warrant for the experimental validation of the final multi-epitope vaccine construct to demonstrate its immunological reinforcing capability and clinical applicability.

15 Apr 2021·The Journal of ImmunologyQ2 · MEDICINE

Glycolipid-Containing Nanoparticle Vaccine Engages Invariant NKT Cells to Enhance Humoral Protection against Systemic Bacterial Infection but Abrogates T-Independent Vaccine Responses

Q2 · MEDICINE

Article

Author: Nash, Kelly ; Vincent, Brandy K ; Weyers, Amanda ; Vomhof-Dekrey, Emilie ; Angel, Daniel ; Yates, Jennifer L ; Durham, Olivia ; Leadbetter, Elizabeth A ; Dudley, Elizabeth ; Shipp, Devon ; Alam, Noran ; Fromme, Rachel ; Mesa, Chloe ; Mohrs, Katya ; Salas, Briana ; Linhardt, Robert J ; Serrata, Adriana ; Miao, Jianjun ; Laughlin, Mitchell ; Lanthier, Paula A ; Shute, Travis ; Amiel, Eyal

AbstractCD4+ T cells enable the critical B cell humoral immune protection afforded by most effective vaccines. We and others have recently identified an alternative source of help for B cells in mice, invariant NK T (iNKT) cells. iNKT cells are innate glycolipid-specific T cells restricted to the nonpolymorphic Ag-presenting molecule CD1d. As such, iNKT cells respond to glycolipids equally well in all people, making them an appealing adjuvant for universal vaccines. We tested the potential for the iNKT glycolipid agonist, α-galactosylceramide (αGC), to serve as an adjuvant for a known human protective epitope by creating a nanoparticle that delivers αGC plus antigenic polysaccharides from Streptococcus pneumoniae. αGC-embedded nanoparticles activate murine iNKT cells and B cells in vitro and in vivo, facilitate significant dose sparing, and avoid iNKT anergy. Nanoparticles containing αGC plus S. pneumoniae polysaccharides elicits robust IgM and IgG in vivo and protect mice against lethal systemic S. pneumoniae. However, codelivery of αGC via nanoparticles actually eliminated Ab protection elicited by a T-independent S. pneumoniae vaccine. This is consistent with previous studies demonstrating iNKT cell help for B cells following acute activation, but negative regulation of B cells during chronic inflammation. αGC-containing nanoparticles represent a viable platform for broadly efficacious vaccines against deadly human pathogens, but their potential for eliminating B cells under certain conditions suggests further clarity on iNKT cell interactions with B cells is warranted.

100 Deals associated with Pneumococcal vaccine recombinant(GlaxoSmithKline Plc)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Infection of ear	Phase 2	United States	GSK Plc	21 May 2012
Otitis Media	Phase 2	United States	GSK Plc	21 May 2012
Streptococcal Infections	Phase 2	Belgium	GSK Plc	18 May 2009

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00985751 (CTgov)	Phase 2	Streptococcal Infections	257	Synflorix (Synflorix Group)	sjzdsiiqya(quetfeexlj) = csdsckepnz pmcdcbzkst (kvlwztdywk, ijqrjwehwo - kqsyneifwo) View more	-	06 Oct 2017
				Synflorix+GSK 2189242A (Synflorix/GSK 2189242A Group)	sjzdsiiqya(quetfeexlj) = nylsuviuup pmcdcbzkst (kvlwztdywk, rspunjmqjd - waygwzwmht)
NCT01545375 (CTgov)	Phase 2	Streptococcal Infections \| Infection of ear \| Otitis Media	1,806	Pneumococcal vaccine GSK2189242A+PedvaxHIB®+Prevnar 13® (dPly-PhtD Group)	lpdztfuljg(pgabdmiolg) = ikyxdnactl hstyciqyss (pujvoelgfn, wtcswpqlqv - sylgkchfjs) View more	-	12 Sep 2017
				Placebo+PedvaxHIB®+Prevnar 13® (Control Group)	lpdztfuljg(pgabdmiolg) = vjkfealyte hstyciqyss (pujvoelgfn, ohuekgqurz - kdjjroryux) View more
NCT00896064 (CTgov)	Phase 2	Streptococcal Infections	43	GSK2189242A (GSK2189242A Formulation 1 Group)	(bwsufvwtfb) = trxaaspngb fdvzgxrpkb (vbxiakeklr, mldifousyo - srrznmbere) View more	-	19 Jul 2017
				GSK2189242A (GSK2189242A Formulation 2 Group)	(bwsufvwtfb) = ctanpvusvm fdvzgxrpkb (vbxiakeklr, ivkpywhjbk - kwuptxwogo) View more
NCT01204658 (CTgov)	Phase 2	Streptococcal Infections	576	Pneumococcal vaccine GSK 2189242A (LD formulation 1)+Infanrix Hexa (DTPa-HBV-IPV/Hib) (10PP-LD/Infanrix Hexa Group)	ttzufxpehs(oebcgogrrr) = iqsfzjbnvr vmzrroywsh (eouucwybkm, nxnyoeauya - opagxvyqkm) View more	-	28 Sep 2016
				Pneumococcal vaccine GSK 2189242A (HD formulation 2)+Infanrix Hexa (DTPa-HBV-IPV/Hib) (10PP-HD/Infanrix Hexa Group)	ttzufxpehs(oebcgogrrr) = gryldjijpf vmzrroywsh (eouucwybkm, hjuqahezge - wkxkmwuqkj) View more